Drugs for Chronic Heart Failure: ACE Inhibitors, Beta‑Blockers, and Aldosterone Antagonists

1. Introduction/Overview

Chronic heart failure (CHF) represents a progressive syndrome in which the myocardium fails to maintain adequate circulating volume and pressure. The pathophysiology involves neurohormonal activation, ventricular remodeling, and impaired cardiac output. Pharmacologic intervention seeks to attenuate maladaptive neurohormonal pathways, improve ventricular function, and reduce morbidity and mortality. In contemporary practice, angiotensin‑converting enzyme inhibitors (ACEIs), β‑adrenergic blockers, and mineralocorticoid receptor antagonists constitute the cornerstone of evidence‑based therapy for CHF with reduced ejection fraction (HFrEF). The integration of these agents has led to substantial improvements in survival and quality of life among affected patients.

• Recognise the neurohormonal mechanisms that drive CHF progression.
• Distinguish the pharmacologic profiles of ACEIs, β‑blockers, and aldosterone antagonists.
• Apply knowledge of drug action, pharmacokinetics, and safety to optimise patient outcomes.
• Identify clinical scenarios that warrant modification of standard therapy.
• Appreciate the importance of monitoring and managing drug‑related adverse effects.

2. Classification

ACE Inhibitors

ACEIs constitute a class of small molecules that inhibit the catalytic activity of angiotensin‑converting enzyme, thereby reducing the formation of angiotensin II and the degradation of bradykinin. Representative agents include enalapril, lisinopril, ramipril, and captopril. Chemically, most ACEIs are peptidomimetics featuring a zinc‑binding motif at the active site.

β‑Blockers

β‑Blockers are heterocyclic sympatholytics that competitively antagonise β‑adrenergic receptors. Their pharmacologic spectrum ranges from selective β1 antagonists (e.g., bisoprolol, metoprolol) to non‑selective agents with intrinsic sympathomimetic activity (e.g., carvedilol). All β‑blockers possess a basic amine linked to a heterocyclic moiety, enabling receptor interaction.

Aldosterone Antagonists

Aldosterone antagonists are selective mineralocorticoid receptor (MR) blockers that impede sodium reabsorption in the distal nephron. Spironolactone and eplerenone are the most widely employed agents, differing in their structural affinity for androgen and progesterone receptors.

3. Mechanism of Action

ACE Inhibitors

By preventing the conversion of angiotensin I to angiotensin II, ACEIs diminish systemic vasoconstriction and aldosterone secretion. The resultant vasodilatory effect lowers afterload, while reduced aldosterone mitigates sodium retention and myocardial fibrosis. Elevated bradykinin levels may further contribute to vasodilation and natriuresis. The net effect is improved cardiac output and attenuation of adverse remodeling.

β‑Blockers

β‑Blockers competitively occupy β1‑adrenergic receptors on ventricular myocytes, curbing sympathetic stimulation. This leads to decreased intracellular cyclic AMP, reduced calcium influx, and lower myocardial oxygen demand. In addition, selective β1 blockade preserves peripheral vasoconstriction mediated by α1 receptors, maintaining systemic vascular resistance. Some β‑blockers possess antioxidant or anti‑apoptotic properties, potentially conferring additional cardioprotective benefits.

Aldosterone Antagonists

By occupying the MR in renal epithelial cells, spironolactone and eplerenone inhibit aldosterone‑mediated sodium reabsorption and potassium excretion. The resulting natriuresis and diuresis alleviate congestion. In the myocardium, MR blockade reduces fibrosis, apoptosis, and inflammatory signalling, thereby moderating ventricular remodeling. The selective binding profile of eplerenone may minimise hormone‑related adverse effects.

4. Pharmacokinetics

ACE Inhibitors

Oral absorption is generally high, though captopril exhibits greater bioavailability in its free form. Distribution is widespread, with plasma protein binding ranging from 40% to 90%. Metabolism predominantly occurs in the liver via CYP450 enzymes (e.g., CYP2C9, CYP3A4) for most ACEIs, while captopril undergoes minimal hepatic conversion. Renal excretion accounts for the majority of elimination, with half‑lives varying from 9 to 18 hours. Dose adjustments are recommended in chronic kidney disease to avoid accumulation.

β‑Blockers

Absorption is rapid for most β‑blockers, with oral bioavailability between 50% and 90%. Distribution volumes differ: selective agents such as metoprolol exhibit moderate tissue penetration, whereas carvedilol demonstrates extensive lipophilic distribution. Metabolism occurs primarily via hepatic CYP3A4 and CYP2D6 pathways. Elimination half‑lives range from 3 to 9 hours, necessitating daily dosing for most agents. Renal function influences clearance, particularly for hydrophilic β‑blockers.

Aldosterone Antagonists

Spironolactone is well absorbed orally, with a bioavailability of approximately 70%. Metabolic activation produces active metabolites (e.g., 7α‑hydroxy‑spironolactone) that contribute to therapeutic effect. Protein binding is high (>90%). Renal excretion is the main route of elimination, and the drug’s half‑life is approximately 24 hours. Eplerenone has a shorter half‑life (~4 hours) but is metabolised by CYP3A4, leading to potential drug interactions.

5. Therapeutic Uses/Clinical Applications

ACE Inhibitors

ACEIs are indicated as first‑line therapy for HFrEF (ejection fraction ≤35%) to reduce mortality, hospitalisation, and progression of disease. They are also recommended post‑myocardial infarction for patients with left ventricular dysfunction and for hypertension with left ventricular hypertrophy. Off‑label, ACEIs may be utilised in diastolic heart failure when hypertension is present, though evidence for mortality benefit is limited.

β‑Blockers

β‑Blockers are prescribed for HFrEF to improve survival, reduce arrhythmia risk, and mitigate sympathetic overdrive. Carvedilol, bisoprolol, and metoprolol succinate are commonly employed. They are also indicated for hypertension, ischemic heart disease, and arrhythmia control. In patients with preserved ejection fraction, β‑blocker benefit remains less definitive, yet they are often considered when concomitant atrial fibrillation or tachyarrhythmias are present.

Aldosterone Antagonists

Spironolactone and eplerenone are indicated for HFrEF with ejection fraction ≤35% and for patients with persistent symptoms despite optimal ACEI/β‑blocker therapy. They are also utilised for hypertensive patients with left ventricular hypertrophy, and for patients with resistant hypertension. Off‑label, aldosterone antagonists may be considered in diastolic dysfunction to reduce fibrosis, although evidence is emerging.

6. Adverse Effects

ACE Inhibitors

• Dry cough (≈10–20%) due to bradykinin accumulation.
• Hypotension, especially post‑dose or with volume depletion.
• Hyperkalaemia, particularly in renal impairment or when combined with potassium‑sparing agents.
• Angioedema (rare, <0.1%) necessitating immediate discontinuation.
• Renal dysfunction: rise in serum creatinine >30 % in susceptible individuals.

β‑Blockers

• Bradycardia and atrioventricular block, more pronounced with high‑dose or non‑selective agents.
• Hypotension, especially during initiation or up‑titration.
• Fatigue, dyspnoea, and depression, possibly due to reduced sympathetic tone.
• Pulmonary exacerbation in patients with asthma or chronic obstructive pulmonary disease.
• Metabolic effects: mild hyperglycaemia and dyslipidaemia in some patients.

Aldosterone Antagonists

• Hyperkalaemia (≈5–10%); monitoring of serum potassium is essential.
• Gynecomastia and sexual dysfunction with spironolactone due to androgen receptor antagonism.
• Renal impairment and decreased creatinine clearance.
• Diarrhoea and gastrointestinal discomfort.
• Rare cases of cough or rash.

7. Drug Interactions

ACE Inhibitors

• Potassium‑sparing diuretics, NSAIDs, and potassium supplements increase hyperkalaemia risk.
• Cimetidine and other CYP3A4 inhibitors may elevate plasma levels of certain ACEIs.
• Concurrent use with other renin–angiotensin system blockers can precipitate acute kidney injury.

β‑Blockers

• Other β‑blockers or calcium‑channel blockers can potentiate bradycardia and hypotension.
• CYP3A4 inhibitors (e.g., ketoconazole) raise serum concentrations of carvedilol and eplerenone.
• Digoxin may have enhanced negative inotropic effects when combined with β‑blockers.
• Antidiabetic agents may mask hypoglycaemic episodes due to blunted adrenergic symptoms.

Aldosterone Antagonists

• Combining spironolactone or eplerenone with ACEIs/ARB and potassium‑sparing diuretics substantially elevates hyperkalaemia risk.
• Warfarin interaction is minimal, but caution is advised when co‑administered with drugs affecting renal function.
• Concurrent use with CYP3A4 inhibitors (e.g., ketoconazole) may increase eplerenone exposure.

8. Special Considerations

Use in Pregnancy/Lactation

• ACEIs are contraindicated in pregnancy, particularly during the second and third trimesters, due to teratogenicity and fetal renal impairment.
• β‑Blockers are generally considered safe in pregnancy but may cause fetal bradycardia or growth restriction; selective agents are preferred.
• Aldosterone antagonists are usually avoided in pregnancy owing to potential for electrolyte disturbances in the fetus.
• Lactation: All three classes are excreted in breast milk; however, the risk–benefit ratio must be weighed against the need for maternal therapy.

Pediatric/Geriatric Considerations

• In pediatrics, dosing is weight‑based, and evidence for mortality benefit is limited; ACEIs and β‑blockers are used for congenital heart disease and hypertension.
• In geriatric patients, renal function often declines; dose adjustments and careful monitoring of potassium and renal parameters are imperative.
• Polypharmacy increases interaction risk; thorough medication reconciliation is essential.

Renal/Hepatic Impairment

• ACEI dosing should be reduced or avoided in severe chronic kidney disease (eGFR <30 mL/min) to prevent hyperkalaemia and renal deterioration.
• β‑Blockers with hepatic metabolism (e.g., carvedilol) may require dose reductions in hepatic failure; hydrophilic agents (e.g., atenolol) may be safer.
• Aldosterone antagonists are contraindicated in severe renal impairment or hyperkalaemia; monitoring of serum creatinine and potassium is mandatory.
• Liver dysfunction may impair metabolism of CYP450‑dependent agents, necessitating dose adjustments.

9. Summary/Key Points

• Neurohormonal blockade via ACEIs, β‑blockers, and aldosterone antagonists remains the foundation of HFrEF management.
• ACEIs reduce angiotensin II and bradykinin‑mediated vasoconstriction, thereby lowering afterload and mitigating fibrosis.
• β‑Blockers attenuate sympathetic overdrive, decrease myocardial oxygen consumption, and improve survival in HFrEF.
• Aldosterone antagonists promote natriuresis and counteract myocardial fibrosis through MR blockade.
• Monitoring of renal function, serum potassium, and blood pressure is essential across all three classes.
• Drug interactions, particularly involving potassium‑sparing agents and CYP450 inhibitors, require vigilant assessment.
• Special populations—pregnancy, elderly, renal/hepatic impairment—demand individualized dosing and close surveillance.
• Clinical decision‑making should integrate evidence, patient comorbidities, and tolerability to optimise outcomes.

References

1. Opie LH, Gersh BJ. Drugs for the Heart. 9th ed. Philadelphia: Elsevier; 2021.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.